|
The following stocks are the leading risers and fallers on AIM on Monday. ---------- AIM - WINNERS ---------- CAP-XX Ltd, up 16% at 0.325 pence, 12-month range 0.1055p-0.455p. Chair Graham Cooley buys 24.0 million shares at 0.265p each on Friday, totalling £63,600. The Sydney-based supercapacitor and energy management systems maker reported on Friday that annual revenue rose 6.5% to A$4.9 million, around £2.4 million, for the year ended June 30, from A$4.6 million. Pretax loss narrowed 36% to A$3.9 million from A$6.1 million. ---------- Eagle Eye PLC, up 9.0% at 278p, 12-month range 199p-488p. Secures a five-year contract with a major North American food retailer operating 450 stores across Texas and Mexico. The provider of software-as-a-service marketing solutions will deploy Eagle Eye’s AIR promotions platform starting in the first half of 2026, though no contract value was disclosed. The contract is expected to go live in the first half of 2026. CEO Tim Mason says: ‘We remain focused on accelerating growth in North America, the biggest loyalty and promotions market in the world.’ ---------- AIM - LOSERS ---------- Buccaneer Energy PLC, down 33% at 0.00975p, 12-month range 0.00975p-0.045p. The Texas-focused exploration company, previously known as Nostra Terra Oil & Gas, says its Allar 1 well in the Pine Mills Field was drilled to 5,767 feet but did not encounter a commercial hydrocarbon accumulation. The well will be plugged and abandoned, with the drilling rig redeployed to the Fouke 4 well nearby. CEO Paul Welch says the result is ‘disappointing’ but provides valuable geological data to refine the field model and de-risk future drilling. Buccaneer continues to generate revenue from existing production as it pursues plans to boost output across the Pine Mills Field. ---------- Cambridge Nutritional Sciences PLC, down 15% at 2.25p, 12-month range 2.25p-4p. The medical diagnostics firm offering health and nutrition products firm reports a pretax loss of £397,000 for the half year ended September 30, widening from £196,000 a year earlier, as revenue falls to £3.9 million from £4.1 million. Gross margin improves to 68% from 65%. The company says full-year sales will be lower than last year as sales cycles lengthen, particularly in Europe and the US. CNS has restructured its sales team to focus on new customer acquisition and growth from existing clients. Chair Carolyn Rand calls the first half ‘frustrating’ but says the firm remains Ebitda positive. ---------- Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
